Filing Details

Accession Number:
0001567619-20-011545
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-02 17:01:44
Reporting Period:
2020-05-29
Accepted Time:
2020-06-02 17:01:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1500399 Giovani Twigge Idexx Laboratories, Inc.
One Idexx Drive
Westbrook ME 04092
Corporate Vice President No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-05-29 12,814 $62.00 25,706 No 4 M Direct
Common Stock Acquisiton 2020-05-29 1,256 $79.54 26,962 No 4 M Direct
Common Stock Disposition 2020-05-29 359 $304.76 26,603 No 4 S Direct
Common Stock Disposition 2020-05-29 1,600 $306.21 25,003 No 4 S Direct
Common Stock Disposition 2020-05-29 3,948 $306.99 21,005 No 4 S Direct
Common Stock Disposition 2020-05-29 3,296 $307.99 17,759 No 4 S Direct
Common Stock Disposition 2020-05-29 4,867 $308.88 12,892 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2020-05-29 12,814 $0.00 12,814 $62.00
Common Stock Incentive Stock Option (right-to-buy) Disposition 2020-05-29 1,256 $0.00 1,256 $79.54
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2024-02-13 No 4 M Direct
0 2025-02-13 No 4 M Direct
Footnotes
  1. Includes 23 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2020.
  2. Represents the weighted average price of the shares sold ranging from a low of $304.46 to a high of $304.98 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  3. Represents the weighted average price of the shares sold ranging from a low of $305.55 to a high of $306.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  4. Represents the weighted average price of the shares sold ranging from a low of $306.58 to a high of $307.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  5. Represents the weighted average price of the shares sold ranging from a low of $307.60 to a high of $308.41 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  6. Represents the weighted average price of the shares sold ranging from a low of $308.62 to a high of $309.40 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
  7. Grant of option to buy 6,407 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning February 14, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  8. Grant of option to buy 628 shares of IDEXX Laboratories, Inc. common stock that became exercisable on February 14, 2020 without giving effect to Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  9. Not applicable.